Clinical Trials

847 enrolled 19 charts

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03798678 2026-05-27

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

36 enrolled

Multiple Myeloma

NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

6,720 enrolled

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT06203912 2026-05-26

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

3 enrolled

Multiple Myeloma

NCT00734877 2026-05-22

TT4B

382 enrolled

Multiple Myeloma

NCT00869232 2026-05-22

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

90 enrolled

Multiple Myeloma

NCT02427620 2026-05-22

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

131 enrolled

Lymphoma, Mantle-Cell

NCT04933539 2026-05-22

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

14 enrolled

Multiple Myeloma

NCT06305754 2026-05-22

MK-2870-009

520 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04302324 2026-05-20

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

11 enrolled 15 charts

Multiple Myeloma

NCT05190705 2026-05-20

Loncastuximab Tesirine in WM

21 enrolled

Waldenstrom Macroglobulinemia

NCT05911321 2026-05-20

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

6 enrolled 5 charts

Multiple Myeloma, Recurrence

NCT03710772 2026-05-19

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

51 enrolled

Lymphoma, Mantle-Cell

NCT03805932 2026-05-19

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Other hematologic neoplasm

18 enrolled 15 charts

Leukemia, Hairy Cell

NCT04432597 2026-05-18

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

GastrointestinalGynecologicHead & Neck

39 enrolled

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Rectal Neoplasms

NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2/3 Active not recruiting

82 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03104842 2026-05-15

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

246 enrolled

Multiple Myeloma

NCT07085728 2026-05-15

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

74 enrolled

Multiple Myeloma

NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

24 enrolled

Immunoglobulin Light-chain Amyloidosis

NCT05497804 2026-05-13

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

17 enrolled

Multiple Myeloma

NCT05514990 2026-05-13

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

10 enrolled

Multiple Myeloma

NCT05981209 2026-05-13

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

12 enrolled

Multiple Myeloma

NCT06169215 2026-05-13

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

70 enrolled

Phase EARLY_PHASE1 Active not recruiting

Multiple Myeloma

NCT04161248 2026-05-12

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

40 enrolled

Lymphoma, B-Cell

NCT00871013 2026-05-11

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

160 enrolled

Neoplasms, Plasma Cell

NCT04181827 2026-05-11

CARTITUDE-4

419 enrolled 10 charts

Multiple Myeloma

NCT05060627 2026-05-11

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

60 enrolled

Multiple Myeloma

NCT05669989 2026-05-11

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

70 enrolled

Multiple Myeloma

NCT05688475 2026-05-11

A Rollover Study of CC-122

LymphoidOther hematologic neoplasmPlasma cell

12 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06230224 2026-05-11

OLYMPIA-4

216 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT04923893 2026-05-08

CARTITUDE-5

743 enrolled

Multiple Myeloma

NCT05083169 2026-05-08

MajesTEC-3

587 enrolled 1 FDA

Multiple Myeloma

NCT05527340 2026-05-08

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

140 enrolled

Multiple Myeloma

NCT06577025 2026-05-08

aMMbition

43 enrolled

Multiple Myeloma

NCT04126200 2026-05-06

DREAMM 5

208 enrolled 5 charts

Phase 2/3 Active not recruiting

Multiple Myeloma

NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

501 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03556332 2026-05-05

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

41 enrolled

Multiple Myeloma

NCT04663347 2026-05-05

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT02343042 2026-05-04

STOMP

300 enrolled

Multiple Myeloma, Recurrence

NCT02883049 2026-05-04

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

5,949 enrolled 28 charts

Burkitt Lymphoma

NCT03007147 2026-05-04

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

475 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03319667 2026-05-04

IMROZ

475 enrolled 1 FDA

Multiple Myeloma

NCT02003222 2026-05-01

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

488 enrolled 13 charts 1 FDA

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04653246 2026-04-30

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

52 enrolled

Multiple Myeloma

NCT04246047 2026-04-23

DREAMM 7

494 enrolled 10 charts 1 FDA

Multiple Myeloma

NCT06868654 2026-04-23

DREAMM 7

72 enrolled 10 charts

Multiple Myeloma

NCT06868667 2026-04-23

DREAMM 7

24 enrolled 10 charts

Multiple Myeloma

NCT05392946 2026-04-21

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

49 enrolled

Multiple Myeloma

NCT02436707 2026-04-20

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

129 enrolled